Snap-8 10 mg

Compound profile

SNAP-8: compound profile, literature landscape and handling notes

Where SNAP-8 came from

SNAP-8 comes from a cosmetic ingredients program rather than a pharmacology program, and recognizing that is the key to reading everything written about it. The design question was posed in reverse from a toxin. Botulinum neurotoxin type A had been characterized well enough by the 1990s that its molecular target was no longer in dispute: it is a protease, and the protein it destroys is SNAP-25. Once that was known, an obvious question followed for anyone working on small synthetic molecules. If the toxin acts by removing SNAP-25 from the assembly that drives vesicle fusion, could some entirely non-toxic molecule interfere with the same assembly by a different and much gentler route?

The answer proposed by a Spanish specialty-ingredients developer in the late 1990s was to take a short stretch of SNAP-25 itself, synthesize it as a free peptide, and rely on it competing with the intact protein for a place in the complex. The first product of that reasoning was a hexapeptide, given the trade name Argireline and the INCI designation acetyl hexapeptide-3, later renumbered to acetyl hexapeptide-8. SNAP-8 is the follow-on: the same peptide extended by two residues, carrying the INCI name acetyl octapeptide-3, and named directly after the protein it is modeled on with the residue count appended.

The INCI numbering deserves a sentence because it causes more confusion than anything else in the naming. Those numbers are positions in a registry index. They are assigned sequentially as ingredients are listed and they encode nothing at all about sequence, length, chemistry or relatedness. Acetyl hexapeptide-3 and acetyl hexapeptide-8 are the same compound under two index entries; acetyl octapeptide-3 and acetyl hexapeptide-3 share a number and are different molecules. Anyone reconciling a vendor label against a paper should ignore the number and work from the sequence in the specification table further down this page.

The practical consequence of this origin is that SNAP-8 has no academic tool-compound tradition behind it. There was no target validation phase, no receptor deorphanization, no medicinal chemistry series published in the open literature. The compound arrived as an ingredient with a mechanistic story attached, and the story has been repeated far more often than it has been tested.

Reading the structure of SNAP-8

The exact sequence string, formula and mass for this listing are printed in the specification table further down this page, taken from the product record rather than restated here. What is worth doing is reading what the eight residues and two blocked termini are for, because in a peptide this short every feature is deliberate.

The core is the hexapeptide sequence shared with Argireline: a pair of acidic residues at the N-terminal end, a methionine, a glutamine and two adjacent arginines. SNAP-8 continues two residues further along the parent protein sequence, adding a small neutral residue and one more acidic side chain. The stated design rationale for the extension is more contact surface for the competitive interaction, on the reasoning that a longer stretch of the mimicked segment presents more of the interface the intact protein would present. Whether the extension actually improves competition is a developer claim supported by developer data rather than an independently established structure-activity finding.

Both termini are blocked. N-terminal acetylation replaces the hydrogen on the free alpha-amino group with an acetyl group. That does three things simultaneously: it removes a positive charge that the segment does not carry in the intact protein, where this stretch is internal rather than terminal; it denies aminopeptidases the free alpha-amino group they require to begin trimming from that end; and it adds a fixed 42-unit increment to the mass, which is useful as an identity check. C-terminal amidation removes the corresponding negative charge and blunts carboxypeptidase attack.

With the termini neutralized, the charge state is set entirely by side chains: three carboxylates against two guanidinium groups, giving a small net negative charge at neutral pH distributed as distinct acidic and basic patches rather than as a uniform polarity. There is no aromatic residue, no cysteine, no hydrophobic face and nothing to nucleate secondary structure. The methionine is the only chemically labile residue in the molecule and it accounts for most of what can go wrong in solution.

The more instructive point is what the fragment lacks relative to the protein it imitates. SNAP-25 is a protein of a little over two hundred residues carrying two separate SNARE motifs joined by a linker that is palmitoylated on a cluster of cysteines, and that lipid modification is how the protein is held at the membrane, since it has no transmembrane segment of its own. An eight-residue peptide has no membrane anchor, no second motif and no capacity to form a four-helix bundle. It is therefore not a functional substitute for SNAP-25. The design intent is occupancy and obstruction, not replacement, and secondary writing that describes SNAP-8 as taking the place of SNAP-25 has misstated the premise.

The target and the pathway in more detail

The target here is not a receptor. It is a protein assembly, and the whole entry turns on understanding what that assembly is and what interfering with it would mean.

Membrane fusion is thermodynamically difficult. Two lipid bilayers approaching each other must shed ordered water and overcome strong repulsion before their leaflets can merge, and nothing about that happens spontaneously at a useful rate. The SNARE proteins are the machinery that supplies the mechanical energy. In the neuronal case the participants are three: synaptobrevin, also called VAMP, which sits in the vesicle membrane; syntaxin-1, which sits in the plasma membrane; and SNAP-25, which is also at the plasma membrane but held there by lipid modification rather than by a membrane-spanning helix. Synaptobrevin contributes one helical SNARE motif, syntaxin contributes one, and SNAP-25 contributes two. Together they assemble into a parallel four-helix bundle.

The assembly is directional. It begins at the membrane-distal ends of the motifs and zippers toward the membrane-proximal ends, and because the two membranes are attached to opposite ends of the forming bundle, zippering physically drags them together. The core of the finished bundle is hydrophobic except for one central layer containing three glutamines and one arginine, which is the basis of the standard Q-SNARE and R-SNARE classification. The completed complex is remarkably stable, resistant to detergent and to considerable heat, and taking it apart afterward requires a dedicated ATP-driven machine, the AAA+ ATPase NSF acting with its adaptor proteins. Calcium sensing and timing are layered on top by synaptotagmin, complexin and the Munc proteins, which regulate assembly rather than perform it.

The premise behind SNAP-8 is that a free peptide corresponding to part of one of SNAP-25's motifs can insert itself into the space that motif would occupy, forming a non-productive arrangement and lowering the rate or the extent of productive four-helix assembly. Several properties follow directly from that premise and they are what make this compound analytically unusual.

There is no saturable high-affinity binding site, so there is no meaningful dissociation constant of the kind quoted for a receptor ligand. The interaction is stoichiometric rather than catalytic, which means useful competition requires the peptide to be present at molar amounts comparable to the protein it competes with, not at trace amounts. It is reversible and occupancy-driven, so removing the peptide removes the effect. And because the assembled bundle is so stable, competition can only act on complexes that are unassembled or partly assembled, which makes the effect kinetic and window-dependent rather than a simple on-off switch. Every one of those properties is the opposite of how a receptor agonist behaves, and importing receptor intuitions here produces wrong expectations.

What the published literature on SNAP-8 actually measures

The published record on SNAP-8 sorts into four categories that differ enormously in rigor, and almost every dispute about this compound comes from citations that cross between them without saying so.

The first category is biochemical SNARE work, and this is the strongest material, though most of it concerns the mechanism rather than the compound. Cell-free assays reconstitute the complex from purified recombinant proteins and read assembly by detergent-resistant complex formation on a gel, by fluorescence resonance energy transfer between labeled motifs, or by lipid mixing between reconstituted proteoliposomes. In this format a competing peptide is added and the reduction in assembly is measured. What such an assay establishes is narrow and real: that a peptide at a stated concentration reduces complex formation between purified proteins in a defined buffer.

The second category is neurosecretory cell work. Chromaffin cells from adrenal medulla are the classical preparation for regulated exocytosis, and catecholamine release from them can be measured by amperometry at single-cell resolution or by bulk assay after stimulation. The founding reports for this peptide family, published in the cosmetic science literature in the early 2000s, used preparations of this kind and described interference with stimulated release. Synaptosome and neuronal culture preparations appear in the same role. These experiments measure secretion from excitable cells in a dish, which is a much more specific claim than the phrasing usually attached to it.

The third category is the applied cosmetic literature, and it is by volume the largest. It consists predominantly of studies commissioned by or performed at ingredient developers, reported in trade journals, technical dossiers and conference material, using instrumental surface-topography endpoints such as silicone replica profilometry or image analysis on small panels of volunteers. Blinding, vehicle controls, randomization, pre-registration and independent replication are variably present and frequently absent. A large fraction of this material was never peer reviewed in any conventional sense.

The fourth category is permeation and formulation science, and it is the most interesting recent work. It consists of Franz diffusion cell experiments on excised skin, tape-stripping studies, quantification of peptide recovered from separated tissue layers, and comparisons of encapsulation strategies including liposomes, ethosomes and various nanocarriers. This literature exists precisely because the permeation question is unresolved, and it is generally more careful than the efficacy literature it is meant to support. It is also the part a bench researcher can most usefully read, because its methods are transferable and its endpoints are analytical rather than perceptual.

Where the SNAP-8 literature is thin or frequently misread

This is the section that matters most for SNAP-8, and it has to be blunt. The evidence base is weak in three independent ways, none usually acknowledged.

The first is provenance. Essentially the entire body of work supporting the applied claims was generated by the cosmetic industry, much of it by the ingredient developers themselves, and much of it exists as technical white papers, marketing dossiers and conference posters rather than peer-reviewed controlled studies. Small unblinded panels without vehicle comparison are common. A claim repeated across thousands of pages can still trace back to a single internal document, and here that is frequently the case. Tracing an assertion back to its primary source is unusually rewarding, because the trail is short and often ends somewhere unexpected.

The second is access, the central unresolved objection. The SNARE complex assembles in the cytoplasm, on the inner face of a plasma membrane, inside a cell. For the competitive premise to operate in intact tissue the peptide must cross the stratum corneum, traverse viable epidermis and reach the cytosol of a specific cell type. An octapeptide of roughly a kilodalton, carrying multiple charged side chains and no hydrophobic character, is far outside the informal 500-dalton guideline for passive permeation through intact stratum corneum, and being charged and hydrophilic makes the subsequent bilayer crossing harder still. This objection is neither obscure nor new. What is remarkable is how often it is simply not addressed: writing about this compound routinely moves from an in vitro competition figure to an applied claim without mentioning that the two are separated by two membranes and a barrier the peptide is not built to cross.

The third is context transfer. The SNARE competition data comes from cell-free reconstitutions and neurosecretory cell preparations with no relation to the tissue context in which the compound is marketed. Chromaffin cells are an excellent model of regulated exocytosis and a poor model of anything else. Reporting that a peptide reduces catecholamine release from adrenal medullary cells in a dish is a statement about adrenal medullary cells in a dish.

A fourth problem is arithmetic. Because the mechanism is stoichiometric rather than catalytic, the concentrations at which competition is demonstrable in vitro are high in molar terms. Anyone asking whether such concentrations could be reached at an intracellular target after transit across a barrier should carry that number through, and most published discussion does not.

How SNAP-8 behaves in solution

SNAP-8 is one of the easier peptides in this catalog to keep in solution and one of the harder ones to tell by eye whether it is still intact.

Solubility is not a problem. With three carboxylates, two guanidinium groups, several polar amide side chains and no hydrophobic face, the peptide dissolves readily in water and in ordinary buffers. The aggregation and surfactant behavior that dominates acylated and amphiphilic peptides is absent: there is nothing to bury and no fold to nucleate on.

Adsorption is more subtle than the low hydrophobicity suggests. Untreated polypropylene is a modest problem here, but glass is another matter. Silanol groups on a glass surface are negatively charged at neutral pH, and the guanidinium groups of the two arginines interact with them in an ion-exchange-like fashion. Arginine-containing peptides can be lost to glass at low concentration in low-ionic-strength buffer, worst at high surface-to-volume ratio. Raising ionic strength suppresses it, as do low-binding plasticware and fewer transfer steps.

Chemical stability in solution is good relative to most peptides but not unconditional, and two reactions account for nearly all of it. The methionine oxidizes to the sulfoxide and, more slowly, to the sulfone, accelerated by dissolved oxygen, trace transition metals, light and peroxide impurities in excipients. Glutamine deamidation is the other, converting an amide side chain to a carboxylate at a rate rising sharply with pH above neutral; the C-terminal amide hydrolyzes by the same chemistry. Both are slow at low temperature and near-neutral pH, and both are cumulative.

Freeze-thaw cycling is less destructive than for a structured peptide, since there is no fold to disrupt, but it is not free. The ice interface concentrates solutes, and in sodium phosphate buffers the two salt forms crystallize at different rates as freezing proceeds, driving the pH of the unfrozen fraction down by more than a unit. Aliquoting once at a working concentration is the answer.

The uncomfortable point is what degraded material looks like: exactly like intact material. Oxidation and deamidation shift mass by 16 and by 1 and precipitate nothing, so there is no turbidity, no color change and no visible signal. Visual inspection has almost no diagnostic value here, and turbidity is more likely to indicate microbial growth than peptide degradation. The storage statement in the specification table is the product record for this material and should be checked against the documentation supplied with the lot.

Analytical notes specific to SNAP-8

Three analytical features are specific to this molecule, and together they explain why a conventional certificate tells you less than its simple structure suggests.

The first is the absence of any aromatic residue: no tryptophan, no tyrosine, no cystine, and therefore essentially no absorbance at 280 nanometers. Detection has to be at around 214 nanometers, where the peptide bond absorbs. That works chromatographically but carries the familiar caveat with unusual force: the 214 nanometer response scales roughly with the number of peptide bonds a species contains, so among short peptides an area-percent figure is not proportional to composition. Shorter impurities are under-represented, longer ones over-represented, and anything co-eluting is invisible entirely. Concentration should come from weighed mass, amino acid analysis, or a chromatographic method calibrated against a reference material.

The second is the acetyl group, the most useful identity handle the molecule offers. Acetylation shifts the mass by a fixed 42 units relative to the free-amine peptide, so an unacetylated batch is immediately distinguishable by mass spectrometry. Incomplete acetylation is a realistic synthesis outcome and an unacetylated batch a realistic substitution, and the free-amine form is a different molecule: it carries an extra positive charge at neutral pH and presents an alpha-amino group that aminopeptidases will act on. Chromatographic separation is possible, but the retention difference under a short gradient may be smaller than expected, so mass is the reliable discriminator.

The third is the oxidation and deamidation family. Methionine sulfoxide is 16 units heavier and generally elutes earlier on a reversed-phase column because it is markedly more polar; the sulfone adds 32. Deamidation of the glutamine side chain and hydrolysis of the C-terminal amide each add roughly 1 unit, which demands enough mass resolution to separate them from the natural isotope pattern of the intact species. That is the realistic impurity profile, and none of it announces itself in the vial.

The relationship to the hexapeptide is analytically trivial and administratively treacherous. SNAP-8 and Argireline differ by two residues, a large mass difference and a clear retention difference, so any competent method separates them. The exposure is at the labeling level: two compounds from one lineage sharing six of eight residues, both sold under index names carrying no structural information, are easy to swap and impossible to tell apart by eye. Identity by mass spectrometry against the sequence in the specification table, not the name, is what settles it.

Compounds researchers confuse with SNAP-8

Questions specific to SNAP-8